Effects of theophylline on radioiodide uptake in MCF-7 breast cancer and NIS gene-transduced SNU-C5 colon cancer cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 2, 2009, Pages 201-208

  Yoon, Joon Kee ^a   Park, Bok Nam ^a   Paik, Jin Young ^b   Jung, Kyung Ho ^b   Ko, Bong Ho ^b   Lee, Kyung Han ^b,c  

^a Ajou University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Cancer; Gene therapy; Radioiodine; Sodium iodide symporter; Theophylline

Indexed keywords

IODINE 125; MONOCLONAL ANTIBODY; POTASSIUM DERIVATIVE; SODIUM IODIDE SYMPORTER; SODIUM IODIDE SYMPORTER MONOCLONAL ANTIBODY; THEOPHYLLINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL MEMBRANE; CELL STRAIN MCF 7; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG RETENTION; DRUG TRANSPORT; DRUG UPTAKE; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; WESTERN BLOTTING;

BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENE THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; SYMPORTERS; THEOPHYLLINE; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 66249138868     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0555     Document Type: Article

References (52)

1. Ringel MD, Ladenson PW. Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Rel Cancer 2004; 11: 97. (Pubitemid 38419726)
2. Mian C, Lacroix L, Bidart JM, et al. Sodium/iodide symporter in thyroid cancer. Exp Clin Endocrinol Diab 2001; 109: 47. (Pubitemid 32154890)
3. Chung JK. Sodium iodide symporter: Its role in nuclear medicine. J Nucl Med 2002; 43: 1188.
4. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309: 937.
5. Schlumberger M, De Vathaire F. [131-iodine: Medical use. Carcinogenic and genetic effects]. Annal Endocrinol 1996; 57: 166. (Pubitemid 26261237)
6. Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Rel Cancer 2006; 13: 797.
7. Sarlis NJ. Metastatic thyroid cancer unresponsive to conventional therapies: Novel management approaches through translational clinical research. Curr Drug Targ Immune Endocr Metabol Disord 2001; 1: 103.
8. Schmutzler C, Winzer R, Meissner-Weigl J, et al. Retinoic acid increases sodium=iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997; 240: 832. (Pubitemid 28271806)
9. Schmutzler C, Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000; 10: 393. (Pubitemid 30418744)
10. Kogai T, Kanamoto Y, Che LH, et al. Systemic retinoic acid treatment induces sodium/iodide symporter expression and radioiodide uptake in mouse breast cancer models. Cancer Res 2004; 64: 415. (Pubitemid 38114126)
11. Kogai T, Schultz JJ, Johnson LS, et al. Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci U S A 2000; 97: 8519. (Pubitemid 30639705)
12. Unterholzner S, Willhauck MJ, Cengic N, et al. Dexamethasone stimulation of retinoic acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells. J Clin Endocrinol Metab 2006; 91: 69. (Pubitemid 43069120)
13. Willhauck MJ, Sharif-Samani B, Senekowitsch-Schmidtke R, et al. Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone. Breast Cancer Res Treat 2008; 109: 263.
14. 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84: 912. (Pubitemid 29138217)
15. Temple R, Berman M, Robbins J, et al. The use of lithium in the treatment of thyrotoxicosis. J Clin Invest 1972; 51: 2746.
16. 99mTc- pertechnetate uptakes and expressions of human sodium iodide symporter gene in breast tumor tissues. Nucl Med Biol 2001; 28: 829. (Pubitemid 32900641)
17. Tazebay UH, Wapnir IL, Levy O, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 2000; 6: 871. (Pubitemid 30644744)
18. 18. Mandell RB, Mandell LZ, Link CJ, Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999; 59: 661.
19. Faivre J, Clerc J, Gerolami R, et al. Long-term radioiodine retention and regression of liver cancer after sodium/iodide symporter gene transfer in Wistar rats. Cancer Res 2004; 64: 8045. (Pubitemid 39446941)
20. Cengic N, Baker CH, Schutz M, et al. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium/iodide symporter gene expression. J Clin Endocrinol Metab 2005; 90: 4457. (Pubitemid 41159327)
21. Scholz IV, Cengic N, Baker CH, et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 2005; 12: 272. (Pubitemid 40220629)
22. Spitzweg C, O'Connor MK, Bergert ER, et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000; 60: 6526.
23. Spitzweg C, Dietz AB, O'Connor MK, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001; 8: 1524. (Pubitemid 33061890)
24. Spitzweg C, Baker CH, Bergert ER, et al. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression. Hum Gene Ther 2007; 18: 916. (Pubitemid 47587318)
25. Dwyer RM, Bergert ER, O'Connor MK, et al. Adenovirusmediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum Gene Ther 2006; 17: 661. (Pubitemid 43967869)
26. Dwyer RM, Bergert ER, O'Connor MK, et al. Sodium/iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther 2006; 13: 60. (Pubitemid 41823852)
27. Dwyer RM, Bergert ER, O'Connor M K, et al. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium/iodide symporter. Clin Cancer Res 2005; 11: 1483. (Pubitemid 40315230)
28. Willhauck MJ, Sharif Samani BR, Klutz K, et al. Alphafetoprotein promoter-targeted sodium/iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 2008; 15: 214.
29. Boland A, Ricard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60: 3484. (Pubitemid 30482168)
30. - symporters for radioiodide concentrator gene therapy. J Nucl Med 2000; 41: 1898.
31. - symporter gene. Endocrinology 1997; 138: 4493. (Pubitemid 27408501)
32. Barnes PJ. Theophylline: New perspectives for an old drug. Am J Resp Crit Care Med 2003; 167: 813.
33. Ahn CS, Rosenberg IN. Prompt stimulation of the organic binding of iodine in the thyroid by adenosine 30', 50'-phosphate in vivo. Proc Natl Acad Sci USA 1968; 60: 830.
34. Hiratani M, Muto K, Oshida Y, et al. Effect of sustainedrelease theophylline administration on pituitary-thyroid axis. J Allerg Clin Immunol 1982; 70: 481. (Pubitemid 13216840)
35. Lee JM, Zemans RL, Hejazi M, et al. Modulation of thyroidal radioiodine uptake by theophylline. Exp Mol Pathol 2004; 77: 116. (Pubitemid 39209293)
36. Reddi PK, Constantinides SM. Partial suppression of tumour production by dibutyryl cyclic AMP and theophylline. Nature 1972; 238: 286.
37. Webb D, Braun W, Plescia OJ. Antitumor effects of polynucleotides and theophylline. Cancer Res 1972; 32: 1814.
38. Tchao R, Leighton J. Inhibitory effect of dibutyryl cyclic AMP and theophylline on the aggregation of human brest tumour cell line BT-20. Nature 1976; 259: 220.
39. Sandlund JT, Neckers LM, Schneller HE, et al. Theophylline induced differentiation provides direct evidence for the deregulation of c-Myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences. Cancer Res 1993; 53: 127. (Pubitemid 23019387)
40. Vassallo R, Lipsky JJ. Theophylline: Recent advances in the understanding of its mode of action and uses in clinical practice. Mayo Clin Proc 1998; 73: 346. (Pubitemid 28169687)
41. Trapasso F, Iuliano R, Chiefari E, et al. Iodide symporter gene expression in normal and transformed rat thyroid cells. Eur J Endocrin Eur Fed Endocr Soc 1999; 140: 447. (Pubitemid 29254013)
42. Venkateswaran A, Marsee DK, Green SH, et al. Forskolin, 8-Br-3', 5'-cyclic adenosine 5' -monophosphate, and catalytic protein kinase A expression in the nucleus increase radioiodide uptake and sodium/iodide symporter protein levels in RET/PTC1-expressing cells. The Journal of clinical endocrinology and metabolism 2004; 89: 6168. (Pubitemid 39628429)
43. Knostman KA, Cho JY, Ryu KY, et al. Signaling through 3', 5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. J Clin Endocrinol Metab 2004; 89: 5196. (Pubitemid 39391469)
44. Arturi F, Ferretti E, Presta I, et al. Regulation of iodide uptake and sodium/iodide symporter expression in the MCF-7 human breast cancer cell line. J Clin Endocrinol Metab 2005; 90: 2321. (Pubitemid 40586280)
45. Zhang B, Liu Y, Harbrecht BG. Cyclic AMP regulate adenovirus mediated inducible nitric oxide synthase expression and CMV promoter activity in cultured hepatocytes. Nitric Oxide 2003; 8: 262. (Pubitemid 36937113)
46. Hunninghake GW, Monick MM, Liu B, et al. The promoterregulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements. J Virol 1989; 63: 3026. (Pubitemid 19156022)
47. Lim SJ, Paeng JC, Kim SJ, et al. Enhanced expression of adenovirus-mediated sodium iodide symporter gene in MCF-7 breast cancer cells with retinoic acid treatment. J Nucl Med 2007; 48: 398.
48. Kronenberg HM, Melmed S, Polonsky KS et al. Williams Textbook of Endocrinology, 11th ed. Philadelphia, PA, Saunders Elsevier, 2008; 301.
49. Wenzel A, Upadhyay G, Schmitt TL, et al. Iodination of proteins in TPO-transfected thyroid cancer cells is independent of NIS. Mol Cellul Endocrinol 2003; 213: 99. (Pubitemid 38229159)
50. Huang M, Batra RK, Kogai T, et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in nonsmall-cell lung cancer. Cancer Gene Ther 2001; 8: 612. (Pubitemid 32786564)
51. Min JJ, Chung JK, Lee YJ, et al. In vitro and in vivo characteristics of a human colon cancer cell line, SNU-C5N, expressing sodium-iodide symporter. Nucl Med Biol 2002; 29: 537.
52. Presta I, Arturi F, Ferretti E, et al. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer 2005; 5: 80. (Pubitemid 41461053)